Which statement about delamanid is true?

• A. Used in MDR-TB/XDR-TB regimens and does not require QT monitoring.
• B. Used only for latent TB.
• C. Requires QT interval monitoring.
• D. Is never used with other drugs.

Answer: (C)

Delamanid has the potential to prolong the QT interval on an ECG, which can raise the risk of serious heart rhythm problems. Because of this, monitoring the QT interval during treatment is essential. Start with a baseline ECG before giving the drug, then check QTc regularly—that’s typically done after starting and at set intervals during therapy, especially if other QT-prolonging drugs are involved or if electrolytes aren’t normal. If the QTc reaches about 500 ms or increases by more than 60 ms from baseline, clinicians usually pause or adjust treatment and correct contributing factors like potassium or magnesium levels. Delamanid is used as part of regimens for multidrug-resistant TB (and has been used in some XDR-TB scenarios), not for latent TB, and it is typically used alongside other anti-TB drugs, with attention to drug interactions that can affect the QT interval. Therefore, the statement that requires QT interval monitoring is the true one.